logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures

Over the next five years, the number of cancer treatments consisting of more than one drug will double, with 68 authorisations expected to be granted

The pharmaceutical industry stresses the importance of paying attention to the peculiarities of these combinations so that people who need them do not face additional difficulties in receiving them

Source: farmaindustria.es

In recent years, the rise of new cancer drugs has been responsible for the increase in efficacy and overall survival of patients. These include combination therapies. These treatments are composed of two or more drugs that are administered together and often include drugs already authorised for other indications and even off-patent. Sometimes, they may be contained in a single drug, but most of those currently authorised are independent drugs, which seek different mechanisms of action and therefore multiply their effect against cancer.

The importance of these combination therapies in cancer treatment, together with the peculiarities they present, have motivated a recent report by the European Federation of the Pharmaceutical Industry (Efpia), entitled Access to cancer combination therapies in Europe: current challenges and solutions. It highlights their importance and a promising scenario for the next five years. They are expected to increase from approximately 10% to 20% of new approvals, according to the document.

However, these therapies are “lagging behind”, says Efpia, in national pricing and reimbursement decisions. “Without further action, limitations in the availability of treatments and their consequences for patients are expected to increase,” the report says, adding that “if this challenge persists, manufacturers may be discouraged from investing in the development of combination therapies, limiting the potential for future research”.

In Spain, one of the countries where information was collected for the report, these barriers to access to combination therapies also exist. “Numerous combinations of drugs are being authorised in Europe that would increase the efficacy against the disease, but they are not reaching patients. This means that we have patients who could have a better approach to the disease. We need the administration to establish clear criteria that will allow their financing and allow them to reach patients without delay,” says Isabel Pineros, director of Farmaindustria’s Access Department.

Combination therapies are, in fact, one of the major therapeutic innovations that will have the greatest impact in 2024 – and are already having an impact – as outlined in Efpia’s pipeline of innovations, published in August 2022.

Challenges and solutions for access

Pineros explains how combination therapies have come on strong in recent years: “Until recently we talked about these treatments as the oncology of the future, but they are already on the table. Progress has been made in research and now it is necessary to make it fundable.

Beyond the old classical chemotherapy combinations, the new immuno-oncology combinations, together with treatments targeting specific genes or proteins, approach cancer in a more personalised way, looking for synergies between molecules and thus beating the disease. “When we talk about cancer, we are not talking about a single disease, so we often tend to compare cases or think that there should be a single treatment for all patients. As research progresses, as the alterations become known, they are going to determine a different evolution. And, therefore, it needs a different approach,” Pineros explains.

The latest Access Indicators for Innovative Therapies in Europe (W.A.I.T.) report reveals that Spain is not in a good situation in terms of access to new cancer drugs. In the period 2018-2021 our country had 57% availability of new drugs, compared to 61% in the previous study. Moreover, in other neighbouring countries availability is much higher, with 72% in France, 76% in England, 83% in Italy and 98% in Germany.

The Farmaindustria spokeswoman stresses the need to seek solutions for combination therapies: “One of the options that could be considered is to establish pricing and reimbursement conditions per indication, instead of per medicine as is currently the case. This would be the best way to achieve funding for medicines when they are to be used in monotherapy and also in indications where they need to be combined with others. With the rise of this type of therapy, the pharmaceutical industry believes in dialogue with the Administration to find a solution to a problem faced by an increasing number of healthcare professionals who want to prescribe the best treatment for their patients.

Efpia’s report also assesses the situation and proposes formulas in which these drugs are evaluated on the basis of results or with systems that take into account that therapies can come from several manufacturers. In the next five years, 68 new cancer combination therapies are expected to be authorised. “There is a clear societal need to develop evaluation and pricing frameworks for combination therapies to ensure that patients have access to them in a timely manner,” the report says.

The aim, as Pineros stresses, is to “ensure that patients in need have access to these therapies and to do so, together with all stakeholders, seek solutions with different approaches and the necessary will, as the pharmaceutical industry has shown”.

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.